ライフサイエンスコーパス: indolent lymphoma

1 ukemia/small lymphocytic lymphoma, and other indolent lymphomas).

2 te relapse, owing to increased relapses with indolent lymphoma.

3 ence of the transformation of the underlying indolent lymphoma.

4 y of obinutuzumab with rituximab in relapsed indolent lymphoma.

5 after induction and safety in patients with indolent lymphoma.

6 ability in patients with relapsed/refractory indolent lymphoma.

7 optimal treatment approach for patients with indolent lymphoma.

8 istics, and outcome of DLBCL with concurrent indolent lymphoma.

9 warranted in untreated and alkylator-failed indolent lymphoma.

10 examethasone (FND) in patients with relapsed indolent lymphoma.

11 cular lymphoma is the most common subtype of indolent lymphoma.

12 s of distinguishing aggressive lymphoma from indolent lymphoma.

13 worse prognosis than those who relapsed with indolent lymphoma.

14 sing activity as a monotherapy in refractory indolent lymphomas.

15 py induces a high LDR rate in HCV-associated indolent lymphomas.

16 d clinical course of patients with so-called indolent lymphomas.

17 mens seem feasible in relapsed or refractory indolent lymphomas.

18 d the only viable treatment strategy for the indolent lymphomas.

19 ost common histological subtype of so-called indolent lymphomas.

20 +/- 0.1, 0.67 +/- 0.13 x 10(-3) mm(2)/s) and indolent lymphoma (0.76 +/- 0.14, 0.84 +/- 0.09 x 10(-3)

21 ween 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have

22 oma (8.0%), large B cell lymphoma (6.1%) and indolent lymphoma (5.7%).

23 lymph nodes with follicular hyperplasia, 26 indolent lymphomas (6 marginal zone lymphomas, 7 small l

24 lapse was higher in patients with concurrent indolent lymphoma (7.4% v 2.1% at 5 years; P < .01).

25 ollicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by the accumulati

26 ctive in patients with recurrent or relapsed indolent lymphoma and results in a high percentage of CR

27 is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard

28 Patients with DLBCL with a concurrent indolent lymphoma and those with the GCB subtype had a h

29 , lasting a median of 3 months (5 months for indolent lymphomas and 3 months for intermediate- to hig

30 g 2-CdA and mitoxantrone in the treatment of indolent lymphoma, and appear to confirm clinically the

31 oclonal antibody therapy, offers promise for indolent lymphoma, and should further improve prognosis

32 iffuse large-B-cell lymphoma, no evidence of indolent lymphoma, and were previously untreated.

33 ffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leu

34 nt in randomised controlled trials (RCTs) of indolent lymphomas, and the association of QOL with surv

35 insights into the underlying biology of the indolent lymphomas are anticipated to help guide therapy

36 Indolent lymphomas are generally incurable, with protrac

37 ars), compared with patients with concurrent indolent lymphoma at diagnosis (5.2%; P = .46).

38 l lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis.

39 Chronic leukemias and indolent lymphomas can be well controlled for years in m

40 In patients with indolent lymphoma, fine needle aspirates were obtained b

41 e 1b, which included patients with DLBCL and indolent lymphomas, four dose levels of venetoclax were

42 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV <or= 13.

43 DLBCL patients with concurrent other indolent lymphoma had similar outcomes compared with pat

44 Patients with concurrent DLBCL and other indolent lymphomas had similar EFS (HR = 1.19) and OS (H

45 ith diffuse large B-cell lymphoma, four with indolent lymphomas) had evidence of clinical activity, a

46 f hematopoietic stem cell transplantation in indolent lymphoma has been defined by the adoption of th

47 otoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging.

48 essive lymphoma is found in a LN biopsy with indolent lymphoma in a BM biopsy.

49 sease and/or the screening and monitoring of indolent lymphoma in individual patients.

50 show that the optimal radiotherapy dose for indolent lymphoma is 24 Gy in 12 fractions when durable

51 re lacking, and it is uncertain whether this indolent lymphoma is defined by age or may occur in adul

52 with organ transplantation in patients with indolent lymphoma is limited, and it is unknown how the

53 with DLBCL than for those who relapsed with indolent lymphoma (median 29.9 months v unreached; P < .

54 eas patients with concurrent DLBCL and other indolent lymphomas (n = 62; 4.7%) had more stage III-IV

55 hieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional

56 FL as a biologically and clinically distinct indolent lymphoma of children and adults characterized b

57 Rituximab as monotherapy for indolent lymphoma of the orbit and conjunctiva may be as

58 e survival (PFS) or overall survival (OS) of indolent lymphoma patients.

59 e large B-cell lymphoma transformed from any indolent lymphoma, primary mediastinal B-cell lymphoma,

60 o many agents available for the treatment of indolent lymphomas, questions that have to be addressed

61 Treatment for patients with stage IV indolent lymphoma ranges from watchful waiting to intens

62 However, the rate of indolent lymphoma relapse was higher in patients with co

63 4.0%; P = .71) subtypes, whereas the rate of indolent lymphoma relapse was higher in patients with th

64 Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing ev

65 total of 175 patients with relapsed CD20(+) indolent lymphoma requiring therapy and with previous re

66 Although most patients with indolent lymphomas respond to initial therapy, virtually

67 Indolent lymphoma should not be considered an absolute c

68 of follicular lymphoma (FL), the most common indolent lymphoma subtype, has been achieved in recent y

69 ns between slope and risk were strongest for indolent lymphoma subtypes.

70 e in this association between aggressive and indolent lymphoma subtypes.

71 aggressive histology, and the remainder had indolent lymphoma subtypes.

72 h relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma.

73 ovides the first phase III data in untreated indolent lymphoma that MR after chemotherapy significant

74 hallenges in the management of patients with indolent lymphoma, the difficulties starting with the di

75 al to profoundly impact clinical outcomes in indolent lymphoma therapy.

76 toxantrone in patients with alkylator-failed indolent lymphoma to determine the maximum-tolerated dos

77 The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemothe

78 patients with previously untreated stage IV indolent lymphoma were evaluable (73 on FND; 69 on ATT).

79 ty-one patients with recurrent or refractory indolent lymphoma were treated with a regimen of fludara

80 e not equivalent when accelerated E mu-N-myc indolent lymphomas were compared to accelerated c-myc pr

81 For example, patients with indolent lymphoma who achieved a complete remission with

82 ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%.

83 FL is an indolent lymphoma with largely favourable outcomes, alth

84 l transplantation is a promising therapy for indolent lymphoma with minimal toxicity and myelosuppres

85 In two patients MC had evolved into an indolent lymphoma with monoclonal B-cell lymphocytosis.

86 ents with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acti

87 improvement in the survival of patients with indolent lymphoma, with patients continuing to have an u

88 DAAs in untreated HCV-positive patients with indolent lymphomas without criteria for immediate conven